We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Mylan declined to voluntarily testify before a Senate committee on its settlement with the Justice Department over its misclassification of the EpiPen for a Medicaid drug rebate program. Read More
Pfizer is suing a Texas health agency for disclosing pricing and rebate information to state lawmakers, alleging the release violates state and federal laws on confidential data. Read More
Pharmaceutical representatives in Chicago must complete a professional education course and be licensed before conducting business, following the unanimous passage of a new ordinance by the city council as part of its plan to combat the opioid epidemic. Read More
A federal judge ruled that a generic version of Merck’s Nasonex developed by Teva Pharmaceuticals does not infringe patent claims covering the allergy treatment’s active ingredient. Read More
Sen. Charles Grassley (R-Iowa) is calling on the Justice Department to reconsider testifying before the House Judiciary Committee on its settlement with Mylan, which resolved allegations that the company overcharged Medicaid for its allergy therapy, the EpiPen. Read More
The UK Court of Appeal affirmed an earlier ruling that invalidates Pfizer’s patent claims for Lyrica, saying generic versions will not lead to any infringement. Read More
A proposal to extend the market exclusivity of new drugs approved in India from four years to 10 is dividing the industry, as some argue that the measure would promote safety and others contend it delays generic competition. Read More